Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals

Lin, Donna Shu-HanDonna Shu-HanLinYu, An-LiAn-LiYuHAO-YUN LOLien, Cheng-WeiCheng-WeiLienJEN-KUANG LEEFU-TIEN CHIANGYU-KANG TU2023-09-282023-09-282023-07-200804-46431479-683Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/635867https://pubmed.ncbi.nlm.nih.gov/37474112/The main target of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the sodium-glucose cotransporters 2, is found in the kidneys, and their activity is reduced in patients with chronic kidney disease (CKD). How the efficacy of SGLT2i may vary in patients with different levels of renal impairment has not been fully elucidated.enSGLT2; cardiovascular outcome; renal outcome[SDGs]SDG3Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individualsjournal article10.1093/ejendo/lvad07837474112